Coherus Oncology (CHRS) Research & Development: 2013-2025
Historic Research & Development for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $27.3 million.
- Coherus Oncology's Research & Development rose 23.58% to $27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.2 million, marking a year-over-year increase of 2.81%. This contributed to the annual value of $93.3 million for FY2024, which is 14.71% down from last year.
- Per Coherus Oncology's latest filing, its Research & Development stood at $27.3 million for Q3 2025, which was up 3.60% from $26.3 million recorded in Q2 2025.
- Over the past 5 years, Coherus Oncology's Research & Development peaked at $203.5 million during Q1 2021, and registered a low of $20.6 million during Q2 2024.
- Over the past 3 years, Coherus Oncology's median Research & Development value was $25.6 million (recorded in 2023), while the average stood at $25.5 million.
- As far as peak fluctuations go, Coherus Oncology's Research & Development spiked by 514.65% in 2021, and later plummeted by 59.25% in 2022.
- Quarterly analysis of 5 years shows Coherus Oncology's Research & Development stood at $50.8 million in 2021, then crashed by 42.83% to $29.0 million in 2022, then fell by 9.14% to $26.4 million in 2023, then fell by 15.57% to $22.3 million in 2024, then rose by 23.58% to $27.3 million in 2025.
- Its last three reported values are $27.3 million in Q3 2025, $26.3 million for Q2 2025, and $24.4 million during Q1 2025.